• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于选择性和高效的 l 型氨基酸转运体 1(LAT1)介导的细胞摄取的结构特性。

Structural properties for selective and efficient l-type amino acid transporter 1 (LAT1) mediated cellular uptake.

机构信息

School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland.

School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland.

出版信息

Int J Pharm. 2018 Jun 10;544(1):91-99. doi: 10.1016/j.ijpharm.2018.04.025. Epub 2018 Apr 15.

DOI:10.1016/j.ijpharm.2018.04.025
PMID:29669256
Abstract

l-Type amino acid transporter 1 (LAT1) is a sodium-independent exchanger transporting large neural amino acids and several amino-acid mimicking drugs across the cell membranes. LAT1 is highly expressed at the blood brain barrier (BBB) and in numerous cancer cells and is therefore a potential drug target. However, structural features affecting the ability to bind to LAT1 and the cellular translocation by LAT1 are unclear. In the present study we determined the binding to and transport through human LAT1 of several compounds into the human breast adenocarcinoma cells (MCF-7). We show that the meta-conjugation of l-phenylalanine increases binding to human LAT1 compared to para-conjugation or aliphatic amino acid moiety. Furthermore, large, rigid and aromatic meta-substituted l-phenylalanine derivative enabled selective and efficient LAT1-mediated cellular uptake. Our results also demonstrates that in addition to binding studies, it is of utmost importance to determine the cellular accumulation of compounds. It provides crucial information on transport efficiency and selectivity of transport mechanisms that the compounds are able to utilize. Overall, these structural findings and the methodology used herein are exploitable to design LAT1-utilizing compounds, such as markers for cancer imaging and drug molecules, enabling more effective and safer treatments for cancer in the future.

摘要

L 型氨基酸转运蛋白 1(LAT1)是一种不依赖于钠的交换体,可将大的神经氨基酸和几种氨基酸模拟药物穿过细胞膜。LAT1 在血脑屏障(BBB)和许多癌细胞中高度表达,因此是一个潜在的药物靶点。然而,影响与 LAT1 结合以及 LAT1 细胞转运能力的结构特征尚不清楚。在本研究中,我们确定了几种化合物与人 LAT1 的结合以及通过人 LAT1 转运到人类乳腺癌腺癌细胞(MCF-7)中的情况。我们表明,与对位共轭或脂肪族氨基酸部分相比,l-苯丙氨酸的间位共轭增加了与人 LAT1 的结合。此外,大的、刚性和芳香性的间位取代的 l-苯丙氨酸衍生物能够实现选择性和有效的 LAT1 介导的细胞摄取。我们的结果还表明,除了结合研究外,确定化合物的细胞积累也非常重要。它提供了有关化合物能够利用的转运机制的转运效率和选择性的关键信息。总的来说,这些结构发现和本文中使用的方法可用于设计利用 LAT1 的化合物,例如癌症成像的标志物和药物分子,从而为未来的癌症提供更有效和更安全的治疗方法。

相似文献

1
Structural properties for selective and efficient l-type amino acid transporter 1 (LAT1) mediated cellular uptake.用于选择性和高效的 l 型氨基酸转运体 1(LAT1)介导的细胞摄取的结构特性。
Int J Pharm. 2018 Jun 10;544(1):91-99. doi: 10.1016/j.ijpharm.2018.04.025. Epub 2018 Apr 15.
2
L-type amino acid transporter 1 utilizing prodrugs: How to achieve effective brain delivery and low systemic exposure of drugs.L 型氨基酸转运体 1 利用前药:如何实现药物的有效脑递送和低系统暴露。
J Control Release. 2017 Sep 10;261:93-104. doi: 10.1016/j.jconrel.2017.06.023. Epub 2017 Jun 27.
3
Targeted Suppression and Knockout of ASCT2 or LAT1 in Epithelial and Mesenchymal Human Liver Cancer Cells Fail to Inhibit Growth.靶向抑制和敲除上皮和间充质人肝癌细胞中的 ASCT2 或 LAT1 并不能抑制其生长。
Int J Mol Sci. 2018 Jul 19;19(7):2093. doi: 10.3390/ijms19072093.
4
Transport of amino acid-related compounds mediated by L-type amino acid transporter 1 (LAT1): insights into the mechanisms of substrate recognition.由L型氨基酸转运体1(LAT1)介导的氨基酸相关化合物的转运:对底物识别机制的深入了解。
Mol Pharmacol. 2002 Apr;61(4):729-37. doi: 10.1124/mol.61.4.729.
5
L-type amino acid transporter 1 utilizing prodrugs of ferulic acid revealed structural features supporting the design of prodrugs for brain delivery.L 型氨基酸转运体 1 利用阿魏酸前药揭示了支持脑递药前药设计的结构特征。
Eur J Pharm Sci. 2019 Mar 1;129:99-109. doi: 10.1016/j.ejps.2019.01.002. Epub 2019 Jan 6.
6
Transport of 3-fluoro-L-α-methyl-tyrosine by tumor-upregulated L-type amino acid transporter 1: a cause of the tumor uptake in PET.肿瘤上调的 L 型氨基酸转运蛋白 1 对 3-氟-L-α-甲基酪氨酸的转运:导致 PET 肿瘤摄取的原因。
J Nucl Med. 2012 Aug;53(8):1253-61. doi: 10.2967/jnumed.112.103069. Epub 2012 Jun 28.
7
Large amino acid transporter 1 (LAT1) prodrugs of valproic acid: new prodrug design ideas for central nervous system delivery.大氨基酸转运蛋白 1(LAT1)丙戊酸前药:中枢神经系统递药的新前药设计思路。
Mol Pharm. 2011 Oct 3;8(5):1857-66. doi: 10.1021/mp2001878. Epub 2011 Aug 9.
8
Reevaluating the Substrate Specificity of the L-Type Amino Acid Transporter (LAT1).重新评估 L 型氨基酸转运体(LAT1)的底物特异性。
J Med Chem. 2018 Aug 23;61(16):7358-7373. doi: 10.1021/acs.jmedchem.8b01007. Epub 2018 Aug 10.
9
Molecular characteristics supporting l-Type amino acid transporter 1 (LAT1)-mediated translocation.支持溶质载体家族 7 成员 11(LAT1)介导转运的分子特征。
Bioorg Chem. 2021 Jul;112:104921. doi: 10.1016/j.bioorg.2021.104921. Epub 2021 Apr 22.
10
The glutamine transporter ASCT2 (SLC1A5) promotes tumor growth independently of the amino acid transporter LAT1 (SLC7A5).谷氨酰胺转运蛋白 ASCT2(SLC1A5)独立于氨基酸转运蛋白 LAT1(SLC7A5)促进肿瘤生长。
J Biol Chem. 2018 Feb 23;293(8):2877-2887. doi: 10.1074/jbc.RA117.001342. Epub 2018 Jan 11.

引用本文的文献

1
Structural basis of anticancer drug recognition and amino acid transport by LAT1.LAT1识别抗癌药物及转运氨基酸的结构基础
Nat Commun. 2025 Feb 14;16(1):1635. doi: 10.1038/s41467-025-56903-w.
2
Radiosynthesis and Preclinical Evaluation of -[F]FET and [F]FET-OMe as Novel [F]FET Analogs for Brain Tumor Imaging.正电子发射断层扫描放射性药物合成与预临床评价:新型 [F]FET 类似物 -[F]FET 和 [F]FET-OMe 用于脑肿瘤成像。
Mol Pharm. 2024 Jun 3;21(6):2795-2812. doi: 10.1021/acs.molpharmaceut.3c01215. Epub 2024 May 15.
3
Sodium-Dependent Neutral Amino Acid Transporter 2 Can Serve as a Tertiary Carrier for l-Type Amino Acid Transporter 1-Utilizing Prodrugs.
钠依赖型中性氨基酸转运蛋白 2 可作为 l 型氨基酸转运蛋白 1 利用前药的三级载体。
Mol Pharm. 2023 Feb 6;20(2):1331-1346. doi: 10.1021/acs.molpharmaceut.2c00948. Epub 2023 Jan 23.
4
Structural Features Affecting the Interactions and Transportability of LAT1-Targeted Phenylalanine Drug Conjugates.影响 LAT1 靶向苯丙氨酸药物偶联物相互作用和可传递性的结构特征。
Mol Pharm. 2023 Jan 2;20(1):206-218. doi: 10.1021/acs.molpharmaceut.2c00594. Epub 2022 Nov 17.
5
Development of Sesamol Carbamate-L-Phenylalanine Prodrug Targeting L-Type Amino Acid Transporter1 (LAT1) as a Potential Antiproliferative Agent against Melanoma.开发 Sesamol 氨基甲酸酯-L-苯丙氨酸前药,靶向 L 型氨基酸转运蛋白 1(LAT1),作为一种潜在的抗黑色素瘤增殖剂。
Int J Mol Sci. 2022 Jul 30;23(15):8446. doi: 10.3390/ijms23158446.
6
A Historical Review of Brain Drug Delivery.脑药物递送的历史回顾
Pharmaceutics. 2022 Jun 16;14(6):1283. doi: 10.3390/pharmaceutics14061283.
7
Increased/Targeted Brain (Pro)Drug Delivery via Utilization of Solute Carriers (SLCs).通过利用溶质载体(SLCs)增加/靶向脑(前体)药物递送。
Pharmaceutics. 2022 Jun 10;14(6):1234. doi: 10.3390/pharmaceutics14061234.
8
Pharmacoproteomics of Brain Barrier Transporters and Substrate Design for the Brain Targeted Drug Delivery.脑屏障转运体的药物蛋白质组学与脑靶向药物递送的底物设计
Pharm Res. 2022 Jul;39(7):1363-1392. doi: 10.1007/s11095-022-03193-2. Epub 2022 Mar 7.
9
Comparison of Experimental Strategies to Study l-Type Amino Acid Transporter 1 (LAT1) Utilization by Ligands.比较研究配体对 l 型氨基酸转运蛋白 1(LAT1)利用的实验策略。
Molecules. 2021 Dec 22;27(1):37. doi: 10.3390/molecules27010037.
10
Pretreatment Effect of Inflammatory Stimuli and Characteristics of Tryptophan Transport on Brain Capillary Endothelial (TR-BBB) and Motor Neuron Like (NSC-34) Cell Lines.炎症刺激的预处理效应及色氨酸转运特性对脑微血管内皮(TR-BBB)和运动神经元样(NSC-34)细胞系的影响
Biomedicines. 2020 Dec 24;9(1):9. doi: 10.3390/biomedicines9010009.